Table 1.

Demographics and clinical characteristics of participants

Characteristic	Baclofen (n=23)	Control (n=12)	p value
Age (yr)	35.2±7	38.2±7.7	0.27
Education (yr)	11.8±1.4	10.8±3.2	0.30
AUD (yr)	10.9±7	11.1±7.4	0.93
Average daily consumption (in alcohol units*) in prior 3 months	18.6±5.6	19.5±10.2	0.69†
Cigarette smokers	10 (83.3)	17 (73.9)	0.53‡
Baclofen dose (mg/day)	57.6±8.9	-	-
PACS score
T0	16.6±6.2	19.3±4.5	0.21
T1	5.4±2.2	7.6±3.4	0.07§
Interval between fMRI scans (day)	14.7±2.6	9.2±3.8	<0.01
Period to first alcohol relapse (day)	60.3±6.2	25.3±7.1¶	0.00||

Values are presented as mean±standard deviation or number (%) except the period to first alcohol relapse which is mean±standard error.

AUD, alcohol use disorder; PACS, Penn Alcohol Craving Scale; T0, Time 0/Pre-treatment; T1, Time 1/Post-treatment; fMRI, functional magnetic resonance imaging.

^*1 Alcohol unit=1 standard drink=10 g of pure alcohol.

^†Mann-Whitney U test,

^‡chi-square test,

^§analysis of covariance accounting for baseline PACS score and number of days between the fMRI scans;

^||Log-rank test.

^¶Three (25%) subjects in the control group who were prescribed an anti-craving medication in the immediate post-discharge period were censored.